Renal Function and the Pharmacokinetics of Neostigmine in Anesthetized Man

Cronnelly, R.; Stanski, Donald R.; Miller, Ronald D.; Sheiner, Lewis B.; Shon, Young-Seok

doi:10.1097/00132586-198008000-00050

Cited by 16 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 The elimination half-life averages 80 min, which is prolonged in patients with renal insufficiency. 24 A randomised, double blind, placebo-controlled trial evaluated neostigmine in patients with ACPO with a cecal diameter of >10 cm and no response to 24 h of conservative therapy. 20 Exclusion criteria were suspected ischemia or perforation, pregnancy, severe active bronchospasm, cardiac arrthythmias, and renal failure.…”

Section: Neostigminementioning

confidence: 99%

Acute colonic pseudo-obstruction

Saunders

2007

Best Practice & Research Clinical Gastroenterology

View full text Add to dashboard Cite

Section: Neostigminementioning

confidence: 99%

Acute colonic pseudo-obstruction

Saunders

2007

Best Practice & Research Clinical Gastroenterology

View full text Add to dashboard Cite

“…Neostigmine, administered intravenously, has a rapid onset of action (1-20 minutes) and short duration (1-2 hours) [18]. Its elimination half-life averages 80 minutes, with a prolonged duration in patients with renal insufficiency [19].…”

Section: Neostigminementioning

confidence: 99%

Acute colonic pseudoobstruction

Saunders

2004

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Acute colonic pseudoobstruction (ACPO) is a clinical condition of acute large bowel obstruction without mechanical blockage. ACPO occurs most often in hospitalized patients with serious underlying medical and surgical conditions. ACPO is an important cause of morbidity and mortality. The pathogenesis of ACPO is not completely understood but likely results from an imbalance in the autonomic regulation of colonic motor function. Metabolic or pharmacologic factors, as well as spinal or retroperitoneal trauma, may alter the autonomic regulation of colonic function, leading to excessive parasympathetic suppression or sympathetic stimulation. This imbalance results in colonic atony and pseudoobstruction. Early recognition and appropriate management are critical to minimizing morbidity and mortality. The mortality rate is estimated at 40% when ischemia or perforation occurs. The best documented treatment of ACPO is intravenous neostigmine, which leads to prompt decompression in the majority of patients after a single infusion. In patients failing or having contraindications to neostigmine, colonoscopic decompression is the active intervention of choice. Surgery is reserved for those with overt peritonitis or perforation.

show abstract

“…Pharmacokinetic parameters for the three anticholinesterase drugs are similar despite different mechanisms of action [8][9][10]. The volume of distribution, elimination halflives, and clearance are similar, yet slightly different.…”

Section: Reversal Of Neuromuscular Blockmentioning

confidence: 96%

“…While neostigmine and pyridostigmine have onset times of 7 to 11 and 12 to 15 minutes, respectively, edrophonium has a shorter onset, of one to two minutes. Currently, neostigmine is the most common anticholinesterase agent used to reverse NMB [7][8][9][10][11].…”

Section: Reversal Of Neuromuscular Blockmentioning

confidence: 99%

“…Because of these side effects, anticholinesterase drugs are concurrently administered with anticholinergic medications such as glycopyrrolate or atropine, which may have significant side effects of their own, including tachycardia, altered cardiac conduction, dysrhythmias, and urinary retention. However, while side effects may occur, when these agents are given appropriately, the incidence of side effects is minimal [6,[10][11][12].…”

Section: Reversal Of Neuromuscular Blockmentioning

confidence: 99%

See 1 more Smart Citation